

the prevention and treatment of HIV infection and infections caused by enveloped viruses causing hemorrhagic fever, systemically, but not topically, utilizing cyanovirin-N, anti-HIV mutants of cyanovirin-N, and anti-HIV fragments of both, but excluding pegylated cyanovirin-N, pegylated anti-HIV mutants of cyanovirin-N and pegylated anti-HIV fragments of both.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: March 26, 2001.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 01-8089 Filed 4-2-01; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: The *ex vivo* use of cyanovirin-N To Remove or Inactivate HIV in Fluid Samples

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a exclusive license worldwide to practice the invention embodied in the patents and patent applications referenced below to OmniViral Therapeutics LLC, of Gaithersburg, MD. The patent rights in these inventions have been assigned to the United States of America.

- (1) U.S. Patent No. 5,821,081, issued Oct. 13, 1998, entitled "Nucleic Acids Encoding Antiviral Proteins and Peptides, Vectors and Host Cells Comprising Same, and Methods of Producing the Antiviral Proteins and Peptides" (PHS Reference No. E-117-95/1)
- (2) U.S. Patent No. 5,843,882, issued Dec. 01, 1998, entitled "Antiviral Proteins and Peptides, DNA, DNA-coding Sequences Therefor, and Uses Thereof" (E-117-95/0)

- (3) U.S. Patent No. 5,998,587, issued Dec. 7, 1999, entitled "Anti-Cyanovirin Antibody" (E-117-95/6)
- (4) U.S. Patent No. 6,015,876, issued Jan. 18, 2000, entitled "Method of Using Cyanovirins" (E-117-95/3)
- (5) U.S. Patent Application No. 09/267,447, filed Mar. 12, 1999, pending, entitled "Cyanovirin Conjugates and Matrix-Anchored Cyanovirin and Related Composition and Methods of Use" (E-074-99/0)
- (6) U.S. Patent Application No. 09/416,434, pending, entitled "Cyanovirin Conjugates and Matrix-Anchored Cyanovirin and Related Composition and Methods of Use" (E-074-99/1)
- (7) PHS Reference Number E-074-99/7, filed 3/22/01, entitled "Glycosylation-Resistant Cyanovirins and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production and Methods of Using Nonglycosylated Cyanovirins"

DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before July 2, 2001 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Sally Hu, Ph.D., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 496-7056, ext. 265; Facsimile: (301) 402-0220; e-mail: hus@od.nih.gov.

SUPPLEMENTARY INFORMATION: The patents and patent applications describe a novel protein, cyanovirin-N, discovered by Dr. Michael R. Boyd and colleagues at the National Cancer Institute. Cyanovirin-N was isolated from a blue-green algae and has been demonstrated to bind avidly to and inactivate the human immunodeficiency virus (HIV).

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 90 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to compositions, devices and methods for the *ex vivo* removal or inactivation of HIV from fluid samples, utilizing cyanovirin-N, anti-HIV mutants of cyanovirin-N, and anti-HIV fragments of

both, but excluding pegylated cyanovirin-N, pegylated anti-HIV mutants of cyanovirin-N and pegylated anti-HIV fragments of both.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: March 26, 2001.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 01-8090 Filed 4-2-01; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

National Toxicology Program (NTP) Board of Scientific Counselors Technical Reports Review Subcommittee Meeting; Review of Draft NTP Technical Reports

Pursuant to Public Law 92-463, notice is hereby given of the next meeting of the NTP Board of Scientific Counselors Technical Reports Review Subcommittee on May 3, 2001 in the Rodbell Auditorium, Rall Building, South Campus, National Institute of Environmental Health Sciences (NIEHS), 111 Alexander Drive, Research Triangle Park, North Carolina. The meeting will begin at 8:30 a.m. on May 3, and is open to the public. The primary agenda topic is the peer review of draft Technical Reports of rodent toxicology and carcinogenesis studies performed by the NTP.

Tentatively scheduled for peer review on May 3, are draft Technical Reports of five 2-year studies, listed alphabetically in the attached table, along with supporting material. Studies were conducted using Fischer 344 rats and/or B6C3F₁ mice. The tentative order of review is given in the far right column of the table.

Draft Reports Available for Public Review and Comment

Approximately one month prior to the meeting, the draft reports will be available for public review on the internet, free of charge, through the Environmental Health Information Service (EHIS) at <http://ehis.niehs.nih.gov>. Printed copies can be obtained, as available, from: Central

Data Management (CDM), NIEHS, P.O. Box 12233, MD E1-02, Research Triangle Park, NC 27709, T: 919-541-3419, FAX: 919-541-3687, or e-mail: CDM@niehs.nih.gov.

The NTP Board of Scientific Counselors Technical Reports Review Subcommittee meeting is open to the public and public comment on any of the Technical Reports is welcome. Time will be provided at the meeting for public comment on each of the reports under review. In order to facilitate planning for the meeting, persons requesting time for an oral presentation on a particular Technical Report are asked to notify the Executive Secretary, Dr. Mary S. Wolfe, at P.O. Box 12233, MD A3-07, Research Triangle Park, NC 27709, T: 919-541-3971, F: 919-541-0295, e-mail: wolfe@niehs.nih.gov. Persons registering to make brief comments are asked to provide, if possible, a written copy of their statement by April 20, to enable review by the Subcommittee and staff prior to the meeting. Written statements can

supplement and may expand the oral presentation. Each speaker is asked to provide his/her name, affiliation, mailing address, phone, fax, e-mail and supporting organization (if any). At least seven minutes will be allotted to each speaker, and if time permits, may be extended to 10 minutes. Each organization is allowed one time slot for each report being reviewed. Registration for making public comments will also be available on-site. If registering on-site to speak and reading oral comments from printed copy, the speaker is asked to bring 25 copies of the text. These copies will be distributed to the Chair and Subcommittee members and supplement the record.

Written comments, in lieu of making oral comments, are also welcome. The comments should include name, affiliation, mailing address, phone, fax, e-mail and sponsoring organization (if any) and preferably be received by April 20, to enable review by the Subcommittee and staff prior to the meeting.

Request for Additional Information

The NTP would welcome receiving toxicology and carcinogenesis information from completed, ongoing or planned studies as well as current production data, human exposure information, and use patterns for any of the chemicals listed in this announcement. Please forward this information to CDM at the address given above. CDM will forward the information to the appropriate staff scientist.

The agenda and a roster of subcommittee members will be available prior to the meeting on the NTP web homepage at <http://ntp-server.niehs.nih.gov> and upon request from the Executive Secretary. Following the meeting, summary minutes will be available on the NTP web homepage and upon request to Dr. Wolfe.

Dated: March 23, 2001.

Samuel H. Wilson,
Deputy Director, National Institute of Environmental Health Sciences.

TECHNICAL REPORTS TENTATIVELY SCHEDULED FOR REVIEW BY THE NTP BOARD OF SCIENTIFIC COUNSELORS TECHNICAL REPORTS REVIEW SUBCOMMITTEE ON MAY 3, 2001

Chemical CAS number	Report No.	Primary uses	Route & exposure levels	Review order
Acrylonitrile 107-13-1 ..	TR-506	Used in the production of acrylic fibers, elastomers, resins, and a variety of chemical or intermediates; annual production is in the millions of tons.	Gavage (deionized water vehicle) Mice: 2.5, 10, or 20 mg/kg	3
Citral 5392-40-5	TR-505	Used in lemon flavoring in foods and beverages and as a lemon fragrance in detergents, perfumes, and toiletries.	Microencapsulated citral in feed Rats: 0, 1000, 2000, or 4000 ppm. Mice: 0, 500, 1000, or 2000 ppm	5
Methacrylonitrile 126-98-7.	TR-497	Used in the production of polymers, elastomers, and plastics including those used in beverage containers.	Gavage (deionized water vehicle) Rats: 0, 3, 10, or 30 mg/kg	4
o-Nitrotoluene 88-72-2	TR-504	Used in synthesis of agricultural and rubber chemicals and of a variety of dyes.	Mice: 0, 1.5, 3, or 6 mg/kg	1
p-Nitrotoluene 99-99-0	TR-498	Used in synthesis of agricultural and rubber chemicals and of a variety of dyes.	Feed Rats: 0, 625, 1250, or 2000 ppm; Male rats: 2000 or 5000 ppm (stop study) Mice: 0, 1250, 2500, or 5000 ppm	2
			Rats & Mice: 0, 1250, 2500, or 5000 ppm	

[FR Doc. 01-8092 Filed 4-2-01; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Agency Information Collection Activities: Proposed Collection; Comment Request

In compliance with section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 concerning opportunity for public comment on

proposed collections of information, the Substance Abuse and Mental Health Services Administration will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the information collection plans, call the SAMHSA Reports Clearance Officer on (301) 443-7978.

Comments are invited on: (a) Whether the proposed collections of information are necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection

of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Proposed Project

Participant Feedback on Training Under the Cooperative Agreement for Mental Health Care Provider Education in HIV/AIDS Program II (OMB No. 0930-0195, Extension)—The Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for